Effects of Enoxaparin at Therapeutic and Prophylactic Doses in COVID-19: A Systematic Review and Meta-Analysis

Vinogradova A. D.
Postgraduate, Chair for Management and Economics of Pharmacy with courses in pharmacognosy, pharmaceutical technology, pharmaceutical and toxicological chemistry¹

Demidova M. A.
Doctor of Medicine, Professor, Head, Chair for Management and Economics of pharmacy with courses in pharmacognosy, pharmaceutical technology, pharmaceutical and toxicological chemistry¹

1 - Tver State Medical University, Tver, Russia

Vinogradova Angela; e-mail: an.vino97@mail.ru.

None declared.

The study had no sponsorship.

Thrombotic complications are the most dangerous manifestations of COVID-19. This justifies the need for anticoagulant therapy in a new coronavirus infection. The effects of enoxaparin at therapeutic and prophylactic doses in COVID-19 were assessed from a meta-analysis of 5 randomized clinical trials (RCTs). Search for RCTs was performed in the MEDLINE, Cochrane, PubMed, and ClinicalTrials.gov databases. Odds ratio (OR) with 95% confidence interval and heterogeneity were calculated applying RevMan 5.4.1 software. Combined criterion for the effectiveness of anticoagulant therapy included mortality and thrombotic events (arterial and venous thrombosis). The safety of enoxaparin was assessed by the frequency of bleeding (secondary outcomes). There were no statistically significant differences in mortality in COVID-19 patients receiving enoxaparin at therapeutic doses compared with prophylactic doses [OR = 0.98; 95% CI 0.84 – 1.16; p = 0.85]. The frequency of thrombosis and thromboembolism when using enoxaparin in therapeutic doses was lower compared with prophylactic doses [OR = 0.80; 95% CI 0.66 – 0.98; p = 0.03], while the frequency of bleeding was higher [OR = 2.11; 95% CI 1.36 – 3.30; p = 0.0009]. This meta-analysis suggests a greater efficacy of enoxaparin at therapeutic doses in reducing the incidence of thrombotic complications in hospitalized COVID-19 patients, however, these data require clarification. Further multicenter randomized controlled trials are needed to determine the optimal anticoagulant regimens in COVID-19 patients.

enoxaparin, meta-analysis, systematic review, COVID-19

10.29234/2308-9113-2022-10-2-41-55

1. Manolis A.S., Manolis T.A., Manolis A.A. et al. COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management. Journal of cardiovascular pharmacology and therapeutics 2021; 26(1): 12-24, doi: 10.1177/1074248420958973

2. Chen E.C., Zon R.L., Battinelli E.M., Connors J.M. Approach to the Patient with COVID-19-Associated Thrombosis: A Case-Based Review. The Oncologist 2020, doi: 10.1634/theoncologist.2020-0682

3. Colling M.E., Kanthi Y. COVID-19-associated coagulopathy: An exploration of mechanisms. Vascular Medicine 2020; 25(5): 471-478, doi: 10.1177/1358863X20932640

4. Franchini M., Marano G., Cruciani M. et al. COVID-19-associated coagulopathy. Diagnosis 2020; 7(4): 357-363, doi: 10.1515/dx-2020-0078

5. Giannis D., Ziogas I.A., Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. Journal of Clinical Virology 2020; 127: 104362, doi: 10.1016/j.jcv.2020.104362

6. Iba T., Connors J.M., Levy J.H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflammation Research 2020; 69(12): 1181-1189, doi: 10.1007/s00011-020-01401-6

7. Katneni U.K., Alexaki A., Hunt R.C. et al. Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. Thrombosis and Haemostasis 2020; 120(12): 1668-1679, doi: 10.1055/s-0040-1715841

8. Vremennye metodicheskie rekomendacii. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versiya 15. [Temporary methodological recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 15.] 2022. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР­_COVID-19­_V15.pdf Accessed: 12.03.2022. (In Russ.)

9. Thachil J., Tang N., Gando S. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of thrombosis and haemostasis 2020; 18(5): 1023-1026, doi: 10.1111/jth.14810

10. Poterucha T.J., Libby P., Goldhaber S.Z. More than an anticoagulant: do heparins have direct anti-inflammatory effects? Thrombosis and Haemostasis 2017; 117(3): 437-444, doi: 10.1160/TH16-08-0620

11. Metodicheskie rekomendacii po provedeniyu meta-analiza. [Methodological recommendations for conducting meta-analysis.] 2017. Available at: https://rosmedex.ru/wp-content/uploads/2018/01/Metodicheskie-rekomendatsii-po-provedeniyu-meta-analiza-2017-g..pdf Accessed: 12.12.2021. (In Russ.)

12. Metodicheskie rekomendacii po ocenke sravnitel'noj klinicheskoj effektivnosti i bezopasnosti lekarstvennogo preparata. [Methodological recommendations for the evaluation of the comparative clinical efficacy and safety of the drug.] 2016. Available at: https://rosmedex.ru/wp-content/uploads/2016/12/MR-E%60B-23.12.2016.pdf Accessed: 12.12.2021. (In Russ.)

13. Goligher E.C, Bradbury C.A, McVerry B.J. et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The New England journal of medicine 2021; 385(9): 777-789, doi: 10.1056/NEJMoa2103417

14. Lopes R.D., de Barros E. Silva P.G.M., Furtado R.H.M. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397(10291): 2253-2263, doi: 10.1016/S0140-6736(21)01203-4

15. Sholzberg M., Tang G.H., Rahhal H. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial. British medical journal 2021; 375(2400), doi: 10.1136/bmj.n2400

16. Sadeghipour P., Talasaz A.H., Rashidi F. et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. Journal of the American Medical Association 2021; 325(16): 1620-1630, doi: 10.1001/jama.2021.4152

17. Spyropoulos A.C., Goldin M., Giannis D. et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. Journal of the American Medical Association 2021; 181(12): 1612-1620, doi: 10.1001/jamainternmed.2021.6203

18. Farkouh M. E., Stone G. W., Lala A. et al. Anticoagulation Strategy [FREEDOM COVID]. (2022). Anticoagulation in Patients With COVID-19: JACC Review Topic of the Week. Journal of the American College of Cardiology 2022; 79(9): 917-928

19. Ayerbe L., Risco C., Ayis S. The association between treatment with heparin and survival in patients with COVID-19. Journal of thrombosis and thrombolysis 2020; 50(2): 298-301, doi: 10.1007/s11239-020-02162-z

20. Paranjpe I., Fuster V., Lala A. et al. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients With COVID-19. Journal of the American College of Cardiology 2020; 76(1): 122-124, doi: 10.1016/j.jacc.2020.05.001

21. Desai A., Voza G., Paiardi S. et al. The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy. International journal of cardiology 2021; 324: 249-254, doi: 10.1016/j.ijcard.2020.09.062

22. Hsu A., Liu Y., Zayac A.S. et al. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. Thrombosis research 2020; 196: 375-378, doi: 10.1016/j.thromres.2020.09.030

23. Gonzalez-Porras J.R., Belhassen-Garcia M., Lopez-Bernus A. et al. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study. São Paulo medical journal = Revista paulista de medicina 2021; 13: 1516, doi: 10.1590/1516-3180.2021.0098.R1.08062021

24. Albani F., Sepe L., Fusina F. et al. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. EClinicalMedicine 2020; 27: 100562, doi: 10.1016/j.eclinm.2020.100562

25. Ionescu F., Jaiyesimi I., Petrescu I. et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis. European journal of haematology 2021; 106(2): 165-174, doi: 10.1111/ejh.13533

26. Nadkarni G.N., Lala A., Bagiella E. et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. Journal of the American College of Cardiology 2020; 76(16): 1815-1826, doi: 10.1016/j.jacc.2020.08.041

27. Billett H.H., Reyes-Gil M., Szymanski J. et al. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. Thrombosis and haemostasis 2020; 120(12): 1691-1699, doi: 10.1055/s-0040-1720978

28. Falcone M., Tiseo G., Barbieri G. et al. Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. Open forum infectious diseases 2020; 7(12): 563, doi: 10.1093/ofid/ofaa563

29. Qin W., Dong F., Zhang Z. et al. Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era. Thrombosis research 2021; 198: 19-22, doi: 10.1016/j.thromres.2020.11.020

30. Rentsch C.T., Beckman J.A., Tomlinson L. et al. Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States. MedRxiv: the preprint server for health sciences 2020; 20246579, doi: 10.1101/2020.12.09.20246579

31. Shen L., Qiu L., Liu D. et al. The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2021; 1-8, doi: 10.1007/s10557-020-07133-3

32. Di Castelnuovo A., Costanzo S., Antinori A. et al. Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and haemostasis 2021; 121(8): 1054-1065, doi: 10.1055/a-1347-6070

33. Al-Samkari H., Gupta S., Karp Leaf R. et al. Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States. Research and practice in thrombosis and haemostasis 2020; 4. (Suppl 1). Available at: https://abstracts.isth.org/abstract/thrombosis-bleeding-and-the-effect-of-anticoagulation-on-survival-in-critically-ill-patients-with-covid-19-in-the-united-states/

34. Parisi R., Costanzo S., Di Castelnuovo A. et al. Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Seminars in thrombosis and hemostasis 2021; 47(4): 372-391, doi: 10.1055/s-0041-1726034

35. Ferguson J., Volk S., Vondracek T. et al. Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS-CoV-2: A Retrospective Cohort Study. Journal of clinical pharmacology 2020; 60(11): 1411-1415, doi: 10.1002/jcph.1749

36. Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis 2021; 18(5): 1094-1099, doi: 10.1111/jth.14817

37. Moonla C., Sosothikul D., Chiasakul T. et al. Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2021; 27: 10760296211008999, doi: 10.1177/10760296211008999

38. Tacquard C., Mansour A., Godon A. et al. Anticoagulation in COVID-19: not strong for too long? Anaesthesia, critical care and pain medicine 2021; 40(2): 100857, doi: 10.1016/j.accpm.2021.100857